Join to access to all OVN content. Join for Free
The MSL Secret Weapon for Insightful Engagement
MSL secret weapon insightful engagement curiosity mindset KOL interactions powerful questions

The MSL Secret Weapon for Insightful Engagement


Share This Article


Summary

In this week’s episode, Mary Winkels, Global Director, Medical Affairs Training and Capability at Vertex Pharmaceuticals discusses the MSL secret weapon for insightful engagement.

Learn more about…

πŸ‘‰ What is the MSL “secret weapon” for insightful engagement
πŸ‘‰ How MSLs can build the curiosity and question asking muscle
πŸ‘‰ The skill gap for most MSLs in KOL interactions
πŸ‘‰ The art of asking powerful questions
πŸ‘‰ The value created by developing a curiosity mindset

Click for Source
MSL secret weapon, insightful engagement, curiosity mindset, KOL interactions, powerful questions

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
The Power of Non Traditional KOL Engagement
Partner Avatar MSL Talk: Tom Caravela, Lindsey Harrer

The Power of Non Traditional KOL Engagement

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Explore OVN